Cargando…

Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands

A subset of the study population from a cross–sectional study of carriership of ESBL/pAmpC–producing E. coli (ESBL–E) in the general population was followed up by five successive samples over an approximate half year period, leading to six samples in 333 persons. Fecal samples were cultured and anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Teunis, Peter F. M., Evers, Eric G., Hengeveld, Paul D., Dierikx, Cindy M., Wielders, Cornelia C. C. H., van Duijkeren, Engeline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862452/
https://www.ncbi.nlm.nih.gov/pubmed/29561861
http://dx.doi.org/10.1371/journal.pone.0193834
_version_ 1783308227897720832
author Teunis, Peter F. M.
Evers, Eric G.
Hengeveld, Paul D.
Dierikx, Cindy M.
Wielders, Cornelia C. C. H.
van Duijkeren, Engeline
author_facet Teunis, Peter F. M.
Evers, Eric G.
Hengeveld, Paul D.
Dierikx, Cindy M.
Wielders, Cornelia C. C. H.
van Duijkeren, Engeline
author_sort Teunis, Peter F. M.
collection PubMed
description A subset of the study population from a cross–sectional study of carriership of ESBL/pAmpC–producing E. coli (ESBL–E) in the general population was followed up by five successive samples over an approximate half year period, leading to six samples in 333 persons. Fecal samples were cultured and analyzed for the presence of E. coli types as characterized by MLST, and ESBL/pAmpC genes were analysed by PCR and sequencing. The study included 255 persons who had a negative first sample, to allow observations of acquiring carriership of ESBL–E. Any individual record thus consisted of a series of snapshots of episodes of presence and absence of ESBL–E carriage. A survival model was built to estimate times to acquire or lose carriership, allowing for any combination of ESBL/pAmpC gene and E. coli MLST type. In carriers, the mean time to lose carriership was 1.1 (95% range 0.8–1.6) years. The estimated mean time to acquire carriership was 3.0 (95% range 1.6–6.3) years. Analysis of these times by ESBL/pAmpC gene found substantial variation among resistance genes both in persistence of carriership and in rates of acquiring carriership: bla(CTX-M-1), bla(CTX-M-14), bla(CTX-M-15), bla(CTX-M-27) and bla(SHV-12) were easily acquired, but bla(CTX-M-1) and bla(SHV-12) were also easily lost, while bla(CTX-M-15), bla(CTX-M-27) and bla(CMY-2) were more likely to persist. When in addition bacterial host types were included, some combinations appeared more persistent than others (bla(CTX-M-1) in ST10 and ST58; bla(CTX-M-14), bla(CMY-2), and bla(SHV-12) in ST69), or were acquired with higher frequency (bla(CTX-M-14) in ST38, ST69, and ST131; bla(CTX-M-15) and bla(CTX-M-27) in ST131; bla(SHV-12) in ST69). The relatively short duration of carriership means that when an intervention drastically reduces the exposure of humans to ESBL-E, the prevalence will be halved in 0.66 years. The observed differences between carriage rates of ESBL/pAmpC genes and E. coli strains need further investigation.
format Online
Article
Text
id pubmed-5862452
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58624522018-03-28 Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands Teunis, Peter F. M. Evers, Eric G. Hengeveld, Paul D. Dierikx, Cindy M. Wielders, Cornelia C. C. H. van Duijkeren, Engeline PLoS One Research Article A subset of the study population from a cross–sectional study of carriership of ESBL/pAmpC–producing E. coli (ESBL–E) in the general population was followed up by five successive samples over an approximate half year period, leading to six samples in 333 persons. Fecal samples were cultured and analyzed for the presence of E. coli types as characterized by MLST, and ESBL/pAmpC genes were analysed by PCR and sequencing. The study included 255 persons who had a negative first sample, to allow observations of acquiring carriership of ESBL–E. Any individual record thus consisted of a series of snapshots of episodes of presence and absence of ESBL–E carriage. A survival model was built to estimate times to acquire or lose carriership, allowing for any combination of ESBL/pAmpC gene and E. coli MLST type. In carriers, the mean time to lose carriership was 1.1 (95% range 0.8–1.6) years. The estimated mean time to acquire carriership was 3.0 (95% range 1.6–6.3) years. Analysis of these times by ESBL/pAmpC gene found substantial variation among resistance genes both in persistence of carriership and in rates of acquiring carriership: bla(CTX-M-1), bla(CTX-M-14), bla(CTX-M-15), bla(CTX-M-27) and bla(SHV-12) were easily acquired, but bla(CTX-M-1) and bla(SHV-12) were also easily lost, while bla(CTX-M-15), bla(CTX-M-27) and bla(CMY-2) were more likely to persist. When in addition bacterial host types were included, some combinations appeared more persistent than others (bla(CTX-M-1) in ST10 and ST58; bla(CTX-M-14), bla(CMY-2), and bla(SHV-12) in ST69), or were acquired with higher frequency (bla(CTX-M-14) in ST38, ST69, and ST131; bla(CTX-M-15) and bla(CTX-M-27) in ST131; bla(SHV-12) in ST69). The relatively short duration of carriership means that when an intervention drastically reduces the exposure of humans to ESBL-E, the prevalence will be halved in 0.66 years. The observed differences between carriage rates of ESBL/pAmpC genes and E. coli strains need further investigation. Public Library of Science 2018-03-21 /pmc/articles/PMC5862452/ /pubmed/29561861 http://dx.doi.org/10.1371/journal.pone.0193834 Text en © 2018 Teunis et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Teunis, Peter F. M.
Evers, Eric G.
Hengeveld, Paul D.
Dierikx, Cindy M.
Wielders, Cornelia C. C. H.
van Duijkeren, Engeline
Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands
title Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands
title_full Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands
title_fullStr Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands
title_full_unstemmed Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands
title_short Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands
title_sort time to acquire and lose carriership of esbl/pampc producing e. coli in humans in the netherlands
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862452/
https://www.ncbi.nlm.nih.gov/pubmed/29561861
http://dx.doi.org/10.1371/journal.pone.0193834
work_keys_str_mv AT teunispeterfm timetoacquireandlosecarriershipofesblpampcproducingecoliinhumansinthenetherlands
AT eversericg timetoacquireandlosecarriershipofesblpampcproducingecoliinhumansinthenetherlands
AT hengeveldpauld timetoacquireandlosecarriershipofesblpampcproducingecoliinhumansinthenetherlands
AT dierikxcindym timetoacquireandlosecarriershipofesblpampcproducingecoliinhumansinthenetherlands
AT wielderscorneliacch timetoacquireandlosecarriershipofesblpampcproducingecoliinhumansinthenetherlands
AT vanduijkerenengeline timetoacquireandlosecarriershipofesblpampcproducingecoliinhumansinthenetherlands